(Q28293647)

2

0 references

Dimitris Mavridis

4

0 references

Werner Kissling

11

0 references

Rolf R. Engel

Rolf R Engel

9

0 references

Loukia M Spineli

Loukia Spineli

3

0 references

Corrado Barbui

8

Corrado Barbui

0 references

John R. Geddes

10

John R Geddes

0 references

author name string

Deniz Orey

5

0 references

Franziska Richter

6

0 references

Myrto Samara

7

0 references

Marko Paul Stapf

12

0 references

Bettina Lässig

13

0 references

John M Davis

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

15

0 references

language of work or name

English

0 references

publication date

14 September 2013

0 references

published in

The Lancet

0 references

volume

382

0 references

page(s)

951-62

0 references

issue

9896

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Validity of indirect comparisons in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

International consensus study of antipsychotic dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Haloperidol versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Chlorpromazine versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Imputing missing standard deviations in meta-analyses can provide accurate results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Evaluation of networks of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Borrowing strength from external trials in a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Checking consistency in mixed treatment comparison meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Haloperidol dose for the acute phase of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Paliperidone for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Perphenazine for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960733-3

7 January 2021

10.1016/S0140-6736(13)60733-3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

711028

711028

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference